Poster Abstracts • OFID 2018:5 (Suppl 1) • S417 metallo-β-lactamases (Ambler Classes A, B, C, and D). In this analysis, we evaluated the activity of cefepime (FEP) in combination with VNRX-5133 and comparators against 1,120 recent Enterobacteriaceae clinical isolates, including carbapenem-resistant strains.
Background. CDI is the leading cause of nosocomial diarrhea associated with 29,000 deaths p.a. in the United States. RDZ is a novel oral drug highly selective for C. difficile limiting collateral damage to the gut microbiota. Here we present a combined analysis of all pharmacokinetic (PK) and tolerability data obtained throughout the development of RDZ from animal models to Phase 2, including new human PK data.
Methods. RDZ levels were measured in plasma and in the GI tract of infected hamster after a single oral dose at 25 mg/kg. Quantitative whole-body autoradiography (QWBA) and excretion mass balance studies were performed in rats following a single 50 mg/kg oral dose of 14 C RDZ. In GLP toxicology studies, RDZ was administered orally for 28 days to dogs and rats at 1,000 mg/kg/day. Toxicokinetic, clinical pathology, and histopathology analysis were performed. The Phase 1 study enrolled 56 healthy male subjects receiving single ascending doses from 2 to 2,000 mg, or, 200 or 500 mg BID for 10 days. The Phase 2 enrolled 100 patients assigned 1:1 to 10 days oral RDZ 200 mg BID or VAN 125 mg QID treatment. Both clinical trials quantified RDZ in plasma and feces, and assessed safety and tolerability.
Results. In all animal studies, plasma levels of RDZ were below or at the limit of quantification (LOQ, 1.0 ng/mL). In the GI tract of hamsters, RDZ levels were highest in the colon. QWBA and excretion studies showed RDZ accumulated in the cecum and colon, the site of infection; >99% of radioactivity was excreted in feces and no radioactivity was detected systemically. 28 days repeat dosing in dog and rat resulted in no observations from treatment, histopathology or in-life parameters. In Phase 1 and 2 studies, RDZ plasma levels were generally near or below the LOQ (0.1 ng/mL). Concomitant medications, CDI severity, and age had no impact on exposure. In Phase 1, AEs were mild with no dose-dependent relationship, occurring and at a similar incidence to placebo. No significant findings from clinical laboratory, ECGs or other assessment were observed. RDZ was well tolerated in Phase 2 with the incidence of AEs and SAEs similar in both RDZ and VAN groups.
Conclusion. In both clinical and nonclinical studies to date, RDZ has been well tolerated and associated with low systemic absorption. Further assessment of safety, tolerability, and PK in Phase 3 studies is warranted.
Disclosures. E. Duperchy, Summit Therapeutics: Employee, Salary. S. Chowdhury, Summit Therapeutics Inc.: Employee and Shareholder, Salary and Shareholder. R. Vickers, Summit Therapeutics: Employee, Salary and Stock options. N. Robinson, Summit Therapeutics: Consultant, Consulting fee. Background. As many as 1.5 million people reside in long-term care facilities in the United States. Nearly all of these patients will develop catheter-associated urinary tract infections (CAUTIs) within a month of catheterization. These infections collectively cost the healthcare system billions of dollars each year. In addition, the emergence of multi-drug-resistant ESKAPE (Enterobacter species, Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterococcus species) pathogens affects the severity of infections, increasing both morbidity and mortality. Our research group is exploring a novel, dual-acting, antimicrobial, glycerol monolaurate (GML)-containing gel to prevent and treat CAUTIs.
A Novel Intravesical Antimicrobial for CAUTIs
Methods. Pieces (7 mm in length) of RenaSil Silicone Tubing were placed in the bladders of BALB/c female mice (n = 5/group). Approximately 1 × 10 8 colony-forming units/mL ESKAPE pathogens (50 µL) were inoculated into the bladder, and animals were returned to cages for 18 hours. One hundred microliters of 2.5% GML Gel (50:50 mix of saline and human-approved glycols) or phosphate-buffered saline (placebo) was administered into the bladders. After 2 hours, animals were euthanized and colony-forming units in bladders and on catheters were determined, and histological analysis of bladders was performed.
Results. GML Gel was bactericidal against ESKAPE pathogens at 2 hours post-treatment. Subsequent histological analysis of bladders from infected and noninfected mice showed that GML Gel was not toxic to bladder tissue.
Conclusion. Our results in this murine catheter infection model indicate that the newly formulated GML Gel may be useful in prevention and treatment of CAUTIs.
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